Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer by Chua, W et al.
Molecular markers of response and toxicity to FOLFOX
chemotherapy in metastatic colorectal cancer
W Chua*,1, D Goldstein
2, CK Lee
3, H Dhillon
4, M Michael
5, P Mitchell
6, SJ Clarke
1 and B Iacopetta
7
1Department of Medical Oncology, Sydney Cancer Centre, Concord Repatriation General Hospital, Sydney, NSW, Australia;
2Department of Medical
Oncology, Prince of Wales Hospital, Concord, NSW, Australia;
3NHMRC Clinical Trials Centre, Sydney, NSW, Australia;
4Centre of Medical Psychology and
Evidence-based Decision-Making, University of Sydney, NSW, Australia;
5Division of Haematology and Medical Oncology, Peter MacCallum Cancer
Centre, Melbourne, Victoria, Australia;
6Department of Medical Oncology, Austin Hospital, Heidelberg, Victoria, Australia;
7School of Surgery, University of
Western Australia, Nedlands, Australia
BACKGROUND: To investigate three genetic alterations (TP53 mutation, Kras mutation and microsatellite instability (MSI)) and three
polymorphisms (methylene tetrahydrofolate reductase (MTHFR) C677T, excision repair cross complementing group 1 (ERCC1)-118
and X-ray repair cross complementing group 1 (XRCC1)-399) for their ability to predict response, survival and toxicity to FOLFOX
first line chemotherapy in the treatment of metastatic colorectal cancer (mCRC).
METHODS: Tumour tissues from 118 mCRC patients who underwent FOLFOX treatment from three successive phase II trials were
evaluated for mutations in TP53 (exons 5–8) and Kras (codons 12 and 13) and for MSI using PCR-based analysis. Genotyping for
common single nucleotide polymorphisms in the MTHFR (codon 677), ERCC1 (codon 118) and XRCC1 (codon 399) genes was also
carried out using PCR techniques. These genetic markers were correlated with clinical response, survival and toxicity to treatment.
RESULTS: Patients with the T allele of ERCC1-118 showed significantly worse progression-free survival in univariate analysis (HR¼2.62;
95% CI¼1.14–6.02; P¼0.02). None of the genetic alterations or polymorphisms showed significant association with clinical
response to FOLFOX. The MTHFR, ERCC1 and XRCC1 polymorphisms showed no associations with overall haematological,
gastrointestinal or neurological toxicity to FOLFOX, although MTHFR 677 TT genotype patients showed a significantly higher
incidence of grade 3 or 4 diarrhoea (26%) compared with CC or CT genotype patients (6%, P¼0.02).
CONCLUSIONS: The ERCC1-118 and MTHFR C677T polymorphisms were associated with progression and severe diarrhoea,
respectively, after FOLFOX treatment in mCRC. Although our findings require confirmation in large prospective studies, they
reinforce the concept that individual genetic variation may allow personalized selection of chemotherapy to optimize clinical
outcomes.
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There have been significant developments in chemotherapy
regimes for the treatment of metastatic colorectal cancer (mCRC)
over the past decade with the introduction of new cytotoxic drugs
including oxaliplatin, irinotecan, capecitabine and biological
agents. Oxaliplatin in combination with a fluoropyrimidine has
become one of the most common first line chemotherapy regimens
used for mCRC and its efficacy has been confirmed in this setting
(Giachetti et al, 2000; de Gramont et al, 2000; Cassidy et al, 2004;
Colucci et al, 2005). The rapidly evolving disciplines of molecular
oncology and pharmacogenetics aim to correlate gene mutations
and polymorphisms, respectively, with drug efficacy and toxicity.
Such information might allow treatments to be tailored to suit
individual patients, thus sparing them from unnecessary toxicity
and expense while still achieving the best response. Numerous
studies have investigated novel predictive factors in tumour tissue
and blood that could allow such individualised therapy. To date,
however, none of these markers has been introduced into routine
clinical practice for the treatment of CRC, with the exception of
recent and consistent evidence for Kras mutation being predictive
for non-response to anti-EGFR treatment (Amado et al, 2008;
Bokemeyer et al, 2008; Karapetis et al, 2008; de Roock et al, 2008;
van Cutsem et al, 2008).
Because of its role in DNA repair, the TP53 gene has been widely
investigated as a possible predictor of response to chemotherapy.
The results of a large international collaborative study indicate
that wild-type TP53 status is predictive of good response to
5-fluorouracil (5-FU)-based therapies in CRC (Russo et al, 2005).
Mutation of the Kras oncogene has also been widely investigated as
a prognostic factor in CRC (Andreyev et al, 1998); however, the
predictive value of this marker for response to 5-FU is less well
known. Another genetic alteration that has received considerable
attention is the microsatellite instability (MSI) phenotype.
Although some studies indicate that MSI is associated with poor
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sresponse to 5-FU (Ribic et al, 2003), others suggest the contrary
(Elsaleh et al, 2000; Kim et al, 2007). In addition to somatic
genetic alterations found in tumour DNA, polymorphisms within
the germline DNA may also have predictive value for response
and toxicity to chemotherapy. This is because single nucleotide
polymorphisms can alter enzyme activity and expression levels.
One of the most well-studied polymorphisms in relation to the
prediction of response and toxicity to 5-FU-based treatments is the
C677T polymorphism in the methylene tetrahydrofolate reductase
(MTHFR) gene (Etienne-Grimaldi et al, 2007). The mutant form of
this gene is associated with lower MTHFR enzymatic activity
leading to changes in the distribution of tissue folates. Similarly,
tumour response to oxaliplatin may be influenced by polymor-
phisms in genes involved in the nucleotide excision repair pathway
(Marsh and McLeod, 2004; Reed, 2005). These include polymor-
phisms in codon 118 (AAC to AAT) of the excision repair cross
complementing group 1 (ERCC1) gene and codon 399 (CGG to
CAG) of the X-ray repair cross complementing group 1 (XRCC1).
Several groups have published on the predictive value of the
ERCC1-118 polymorphism for response to oxaliplatin treatment in
mCRC (Stoehlmacher et al, 2004; Viguier et al, 2005; Moreno et al,
2006; Ruzzo et al, 2007; Martinez-Balibrea et al, 2008; Pare et al,
2008), although the results have not been consistent. Less work has
been published on the XRCC1-399 polymorphism and again
the results have not been concordant (Stoehlmacher et al, 2004;
Ruzzo et al, 2007; Pare et al, 2008).
The aim of this study was to evaluate three genetic alterations
(TP53 mutation, Kras mutation and MSI) and three polymor-
phisms (MTHFR C677T, ERCC1-118 and XRCC1-399) for their
ability to predict response and toxicity to FOLFOX first line
chemotherapy in the treatment of mCRC. Tissue samples were
obtained from patients enrolled in three successive and prospec-
tive phase II trials investigating modifications of the FOLFOX4
regimen and the utility of gabapentin for reduction of oxaliplatin-
based neuropathy (Goldstein et al, 2005; Michael et al, 2006;
Mitchell et al, 2006).
MATERIALS AND METHODS
The eligibility criteria for inclusion in the trials have been
described earlier (Goldstein et al, 2005; Michael et al, 2006;
Mitchell et al, 2006). Patients with a histologically confirmed
diagnosis of advanced stage adenocarcinoma of the colon or
rectum, who were chemotherapy naive were eligible to enter these
trials. Patients were required to have measurable disease, adequate
organ function, good performance status (ECOG performance
status 0–2) and to have completed adjuvant treatment at least
6 months before entry into the trial. Patients were excluded if they
had received earlier adjuvant chemotherapy with oxaliplatin. This
substudy of molecular markers was performed with the approval
of the individual institutional ethics committees where patients
received treatment. A total of 134 patients were enrolled in the
three trials and of these, primary tumour tissue samples were
available for 118 (88%) patients.
Molecular analyses
Formalin fixed and paraffin-embedded tumour tissue blocks of
surgical resection or biopsy specimens were retrieved from
pathology archives. After histological confirmation of tumour cell
content, several 10-mm sections were cut and the DNA extracted
for PCR amplification as described earlier (Soong and Iacopetta,
1997). Fluorescent single strand conformation polymorphism
analysis (SSCP) was used to screen for mutations in exons 5–8
of TP53 (Iacopetta et al, 2000a), codons 12 and 13 of Kras (Wang
et al, 2003) and for MSI in the BAT-26 mononucleotide repeat
(Iacopetta and Grieu, 2000b). Fluorescent SSCP was also used to
determine the MTHFR C677T genotype (Grieu et al, 2004).
Genotyping for the ERCC1 codon 118 (C4T) and XRCC1 codon
399 (G4A) polymorphisms was carried out using the BsrDI
(Biolab, Australia) and MspI (Promega, Australia) restriction
enzymes and the PCR primers and conditions described earlier
(Stoehlmacher et al, 2004).
Chemotherapy response, toxicity and survival
Chemotherapy cycles were administered every 2 weeks until
disease progression or the development of unacceptable toxicity.
Radiological response was assessed as per the World Health
Organisation Criteria (Miller et al, 1981). All toxicity was graded
according to the National Cancer Institute Common Toxicity
Criteria and toxicity assessments performed at day 1 of every cycle
until the end of treatment. For this study, patients with complete
or partial response were classified as responders, and patients
with stable disease or progressive disease were classified as
non-responders. Patients were also analysed according to disease
stabilisation (complete response, partial response and stable
disease) and progressive disease. Progression-free survival (PFS)
was defined as the time from patient registration on clinical trial
until the first documented tumour progression or death from any
cause. Overall survival (OS) was defined as the time from patient
registration to death from any cause.
Statistical analysis
Fisher’s exact tests were used to access association between
genotypes and polymorphisms with response or toxicity outcome.
Odds ratio and 95% confidence intervals (CIs) were reported on
the basis of univariate logistic regression models. Time to event
data were analysed using the Kaplan–Meier method. Hazard ratio
(HR) and 95% CI were reported on the basis of univariate
Cox proportion hazards regression analyses. No adjustment to the
P-value was performed for multiple testing. Multivariate models
were also constructed to evaluate the effect of genotypes and
polymorphisms on PFS and OS after adjustment for other
prognostic factors.
RESULTS
Clinical characteristics for the 118 patients evaluated in this study
are shown in Table 1. Patients were predominantly male (68%)
and the median age at diagnosis was 61 years (range, 31–75 years).
A total of 102 patients (86%) had an ECOG performance status
of 0 or 1. There was no evidence of heterogeneity in patient
characteristics across the three trials. Information on clinical
response to treatment was available for 106 patients, of whom 58
(55%) showed complete or partial response. The median PFS was
7.5 months (95% CI¼6.0–8.6 months) and median OS was 16.3
months (95% CI¼13.7–21.1 months). Major adverse events
(grade 3 or 4 toxicity) were neutropenia (36% of patients),
neurological toxicity (17%) and diarrhoea (9%).
Tumour samples for the 118 patients were analyzed at a single
institution for the presence of mutations and for genotype status.
No results for any marker were obtained for 1 patient, for MSI and
MTHFR genotype in 2 patients, and for TP53 mutation, ERCC1 and
XRCC1 genotypes in 3 patients.
TP53 mutation was found in 43 out of 115 (37%) cases, Kras
mutation in 37 out of 117 (32%) cases and MSIþ in 2 out of 116
(2%) cases. TP53 and Kras mutations showed no significant
associations with clinical response to FOLFOX treatment. Only two
cases showed MSI, of which one was associated with clinical
response and the other was not. Genotype frequencies for MTHFR
C677T were 37% (CC), 47% (CT) and 16% (TT), for ERCC1-118
they were 9% (CC), 56% (CT) and 35% (TT), whereas for XRCC1-
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s399 they were 34% (GG), 53% (GA) and 13% (AA). No significant
associations were seen between these polymorphisms and clinical
response (Table 2) or disease stabilization (data not shown).
The ERCC1-118 polymorphism was significantly linked to PFS in
univariate analysis (Table 3; Figure 1). Patients carrying a C/T or
T/T genotype showed significantly worse PFS compared with those
with the CC genotype (HR¼2.62; 95% CI¼1.14–6.02; P¼0.02),
but not for OS (P¼0.2). The median PFS for patients with the
ERCC1-118 CC genotype was 8.7 months compared with 7.5
months for those with at least one T allele. In multivariate
analysis, the association between ERCC1-118 genotype and
PFS approached statistical significance (P¼0.07; Table 4). TP53
mutation, Kras mutation, MTHFR genotype and XRCC1 genotype
were not associated with either PFS or OS (Table 3).
Somatic mutations are restricted to tumour tissue and
were, therefore, not analyzed in relation to the prediction of
systemic toxicity to treatment. The MTHFR-C677T, ERCC1-118
and XRCC1-399 polymorphisms showed no significant associa-
tions with overall haematological, gastrointestinal or neurological
toxicity to treatment (Table 5). There were no associations
when the results were analysed for toxicity after 3 or 6 months
on treatment or the entire course of chemotherapy. Although
only 11 patients experienced grade 3 or 4 diarrhoea, the MTHFR
TT genotype was over-represented in this group (Table 6). The
percentage of cases who suffered this severe toxicity was
significantly higher for TT genotype patients (5 out of 19, 26%)
than for CC or CT genotype patients (6 out of 97, 6%; P¼0.02,
Fisher’s exact test).
DISCUSSION
The aims of this study were to investigate the associations of TP53
mutation, Kras mutation and MSI and response to FOLFOX in
mCRC, as well as the predictive values of polymorphisms in
MTHFR, ERCC1 and XRCC1 for both response and toxicity to this
treatment. These genetic markers were evaluated in 118 patients,
of which clinical response data were available for 106 patients. The
frequencies of TP53 mutation (37%) and Kras mutation (32%)
observed here are similar to those reported in other large studies
of CRC (Andreyev et al, 1998; Russo et al, 2005). The very low
frequency of MSIþ (2%) is in keeping with the low propensity
for these tumours to metastasise (Jass, 2006) and prevented
investigation of the predictive value of this molecular marker in
the current study of mCRC. The distribution of ERCC1 and XRCC1
polymorphisms were similar to those described in other Caucasian
populations (Ruzzo et al, 2008) with a slightly higher frequency of
the MTHFR 677 CC genotype in our population.
The TP53 gene has important functions in DNA damage repair
and apoptosis (Royds and Iacopetta, 2006). Its lack of association
with response and survival to FOLFOX in this study (Tables 2
and 3) was therefore surprising and contrary to a large study
reporting the impact of TP53 on patients with Dukes’ C tumours
treated with 5-fluorouracil as adjuvant chemotherapy (Russo et al,
2005). The current finding that Kras mutation is not associated
with response to FOLFOX supports an earlier study with 5-FU
monotherapy (Etienne-Grimaldi et al, 2008). However, the strong
predictive value of Kras mutation for response to anti-EGFR
therapies has now been clearly established for mCRC (Amado et al,
2008; Bokemeyer et al, 2008; de Roock et al, 2008; Karapetis et al,
2008; van Cutsem et al, 2008). The MTHFR enzyme has a central
function in regulating the pool of intracellular folates available for
nucleic acid synthesis and DNA methylation. The common C677T
polymorphism in MTHFR shows reduced enzyme activity that is
hypothesized to increase intracellular folate concentrations and
therefore increase sensitivity to fluoropyrimidines (Sohn et al,
2004). In support of this, human cancer cell lines with the MTHFR
677 T allele show greater sensitivity to 5-FU compared with those
with the C allele (Sohn et al, 2004) and this was confirmed in a
study of 98 CRC patients treated with 5-FU-based chemotherapy
Table 2 Clinical response according to molecular features
Patients Clinical response
a
Marker n % Odds ratio 95% CI P
TP53 mutation
Absent 72 63 1.00
Present 43 37 1.67 0.74–3.73 0.2
Kras mutation
Absent 80 68 1.00
Present 37 32 1.21 0.54–2.73 0.6
MSI
Absent 114 98 1.00
Present 2 2 0.79 0.05–12.97 0.9
MTHFR 677
CC 43 37 1.00
CT 54 47 0.42 0.18–0.99 0.05
TT 19 16 0.67 0.20–2.17 0.5
CT and TT 73 63 0.47 0.21–1.06 0.07
ERCC1-118
CC 10 9 1.00
CT 64 56 0.35 0.06–1.86 0.2
TT 41 35 0.51 0.09–2.88 0.4
CT and TT 105 91 0.40 0.08–2.10 0.3
XRCC1-399
GG 39 34 1.00
AG 61 53 1.00 0.43–2.34 1.0
AA 15 13 1.28 0.35–4.68 0.7
AG and AA 76 66 1.05 0.46–2.37 0.9
aComplete response/partial response vs stable disease/progressive disease.
Table 1 Baseline characteristics of mCRC patients
Characteristic n %
Total number 118 100
Gender
Male 80 68
Female 38 32
Primary tumour
Colon 82 70
Rectum 36 30
Ethnic origin
Caucasian 114 96
Asian 2 2
Others 2 2
ECOG performance status
05 0 4 2
15 2 4 4
21 4 1 2
Prior adjuvant chemotherapy
Yes 83 70
No 35 30
Carcinoembryonic antigen (mgl
-1)1 7
Median (range) (0–12, 900)
mCRC¼metastatic colorectal cancer.
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s(Etienne et al, 2004). Similarly, patients with the MTHFR T allele
are postulated to experience greater toxicity from fluoro-
pyrimidine-based chemotherapy (Sharma et al, 2008).
The MTHFR C677T polymorphism was not associated with
response to FOLFOX in this study. This result concurs with several
other studies that used FOLFOX or FOLFIRI (Marcuello et al, 2006;
Suh et al, 2006; Ruzzo et al, 2007) but not with two others that
used 5-FU monotherapy and reported better response for patients
with the TT genotype (Jakobsen et al, 2005; Etienne-Grimaldi
et al, 2007). Thus, it appears that the type of chemotherapy
regimen used could influence the predictive value observed for the
MTHFR C677T polymorphism. A retrospective study reported the
MTHFR A1298C polymorphism was associated with survival in
5-FU-treated mCRC, but only in female patients (Zhang et al,
2008). This polymorphism is in strong linkage disequilibrium
with the C677T polymorphism; however, no gender difference
in predictive value was observed here for the MTHFR C677T
polymorphism.
Only a few studies have investigated MTHFR genotype as a
predictor of toxicity to 5-FU-based chemotherapy and to our
knowledge there have been no reports in relation to FOLFOX. The
MTHFR C677T polymorphism was not associated with worse grade
3 or 4 haematological, gastrointestinal or neurological toxicity
Table 3 Univariate Cox proportional hazards regression for progression-
free survival (PFS) and overall survival (OS)
Patients PFS OS
Marker n % HR 95% CI P HR 95% CI P
TP53 mutation
Absent 72 63 1.00 1.00
Present 43 37 0.85 0.58–1.26 0.4 0.88 0.56–1.37 0.6
Kras mutation
Absent 80 68 1.00 1.00
Present 37 32 0.91 0.60–1.36 0.6 0.76 0.48–1.21 0.2
MSI
Absent 114 98 1.00 1.00
Present 2 2 0.36 0.05–2.62 0.3 0.40 0.06–2.92 0.4
MTHFR 677
CC 43 37 1.00 1.00
CT 54 47 0.81 0.53–1.24 0.3 1.10 0.68–1.76 0.7
TT 19 16 1.05 0.61–1.81 0.9 1.35 0.75–2.45 0.3
CT and TT 73 63 0.87 0.59–1.29 0.5 1.16 0.75–1.81 0.5
ERCC1-118
CC 10 9 1.00 1.00
CT 64 56 2.68 1.15–6.23 0.02 1.88 0.75–4.71 0.2
TT 41 35 2.54 1.07–6.04 0.04 1.55 0.60–4.00 0.4
CT and TT 105 91 2.62 1.14–6.02 0.02 1.74 0.70–4.30 0.2
XRCC1-399
GG 39 34 1.00 1.00
AG 61 53 0.57 0.28–1.19 0.1 0.92 0.58–1.45 0.7
AA 15 13 1.01 0.39–2.60 1.0 0.52 0.24–1.14 0.1
AG and AA 76 66 0.66 0.34–1.28 0.2 0.83 0.53–1.29 0.4
Logrank P=0.02
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ERCC1-118 CT and TT
ERCC1-118 CC
Number at risk
0 5 1 01 52 02 5
Number of months
ERCC1-118 CC
Progression-free survival
105 5 11 14 32 78
10 3 4 4 5 8
ERCC1-118 CT and TT
Figure 1 Progression-free survival and ERCC1-118 polymorphism.
Table 4 Multivariable analysis of clinical and molecular factors and PFS
Variable Hazard ratio 95% CI P
Number of organs involved
1 1.00
41 1.62 1.21–2.15 0.001
Absolute neutrophil count at baseline
o ULN
a 1.00
XULN 1.12 1.03–1.21 0.009
ERCC1-118
CC 1.00
CT and TT 2.16 0.94–4.97 0.07
aThe upper limit of normal (ULN) for neutrophils was 7 10
9 per litre.
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s(Table 5). However, patients with the TT genotype suffered
a significantly higher incidence of grades 3–4 diarrhoea (5 out of
19, 26%) compared with those with the CC or CT genotype (6 out
of 97, 6%; Table 6). Interestingly, an earlier study with UFT/
leucovorin found that 1 of 2 patients with the MTHFR TT genotype
developed grade 3 diarrhoea at the first dose level (Veronese et al,
2004). Preliminary data published in abstract form suggest that
75% of patients receiving adjuvant 5-FU-based chemotherapy who
had combined MTHFR 677 TT and 1298 AA genotypes predicted
for severe grades 3–4 toxicities (Adamo et al, 2008). However, a
large German study found that neither the MTHFR C677T nor the
A1298C polymorphisms were associated with toxicity to 5-FU in
cancer patients (Schwab et al, 2008), supporting earlier observa-
tions in patients treated with 5-FU monotherapy (Cohen et al,
2003), FOLFOX (Ruzzo et al, 2007) or FOLFIRI (Ruzzo et al, 2008).
Capitain et al (2008) reported the A1298C polymorphism, but not
C677T, was predictive of toxicity to 5-FU (Capitain et al, 2008).
Clearly, more work in larger cohorts that includes analysis of both
MTHFR polymorphisms is required to determine whether these
genetic variants are associated with 5-FU toxicity to, particularly
for diarrhoea. The collection of additional information on blood or
tissue folate status would also be very useful in helping to clarify
the predictive significance of MTHFR polymorphisms.
ERCC1 and XRCC1 are both involved in the repair of DNA
damage and hence functional variants of these genes are candidate
predictive markers for response to oxaliplatin. Unfortunately,
results to date on the predictive value of the ERCC1-118
polymorphism for response to oxaliplatin-based chemotherapy
have been inconsistent. Several groups have reported that mCRC
patients with the ERCC1-118 TT or CT genotype had better tumour
response or survival compared with CC patients (Viguier et al,
2005; Moreno et al, 2006; Martinez-Balibrea et al, 2008; Pare et al,
2008). However, two groups reported the T allele was associated
with worse survival (Park et al, 2002; Ruzzo et al, 2007).
Stoehlmacher et al (2004) reported a two-fold increase risk of
dying for patients with the C/T or T/T genotype compared with
those with a C/C genotype (Stoehlmacher et al, 2004). Consistent
with the results by Ruzzo et al (2007) and Stoehlmacher et al
(2004), patients in this study with an ERCC1-118 CT or TT
genotype had a 2.6-fold greater risk of progression with FOLFOX
chemotherapy compared with those with the CC genotype. In
multivariate analysis, this result approached statistical significance
(HR¼2.16; 95% CI¼0.94–4.97; P¼0.07), with organ involvement
and baseline neutrophil count being significant for PFS (Table 3).
Our multivariate analysis replicated a recent report highlighting
the value of clinical factors in predicting risk (Sanoff et al, 2008).
ERCC1 protein expression was not assessed in this; however, two
earlier studies reported an association between low expression of
ERCC1 (mRNA and protein) and improved overall survival in CRC
(Shirota et al, 2001; Kim et al, 2009).
Park et al (2002) earlier showed a trend towards higher mRNA
levels with increasing numbers of ERCC1-118 T alleles (Park et al,
2002). ERCC1 is important for the removal of DNA adducts caused
by platinum compounds and hence the increased gene expression
in CT and TT individuals may lead to treatment resistance. This
could explain the worse PFS seen for these individuals in this study
of FOLFOX treatment (Table 3). However, contrary results have
been found in studies of ovarian cell lines, where the ERCC1 codon
118 C–T substitution was associated with reduced levels of ERCC1
mRNA and protein expression (Yu et al, 2000). The functional
consequences of the silent ERCC1-118 polymorphism, therefore,
remain unclear and may vary according to tissue type. The
contrasting results from clinical studies of this ERCC-1 poly-
morphism may be due to small sample sizes and type I (false
positive) rates, with more definitive results likely to be achieved
through meta-analysis (Pajak et al, 2000).
Fewer studies have been carried out on polymorphisms in
XRCC1 as an important factor for response to oxaliplatin-based
chemotherapy. An initial report on the XRCC1-399 polymorphism
suggested an association with response (Stoehlmacher et al, 2001);
however, subsequent studies including one by the same group
failed to confirm this finding (Stoehlmacher et al, 2004; Ruzzo
et al, 2007; Pare et al, 2008). This study also failed to confirm
an association between XRCC1-399 polymorphism and response or
survival to FOLFOX (Tables 2 and 3). The lack of association with
overall toxicity (Table 5) also suggests that ERCC1 and XRCC1 are
not involved in adverse reactions to FOLFOX treatment, consistent
with results from other studies (Ruzzo et al, 2007). In our study,
there was also no correlation between neurotoxicity and response,
Table 5 Associations between polymorphisms and overall haematological, gastrointestinal and neurological toxicity
Haematological Gastrointestinal Neurological
0–2 3–4 0–2 3–4 0–2 3–4
Genotype n % n % Pn% n % Pn % n % P
MTHFR 677
CC 24 56 19 44 37 86 6 14 33 77 10 23
CT 40 74 14 26 50 93 4 7 49 91 5 9
TT 12 63 7 37 0.17 14 74 5 26 0.10 14 74 5 26 0.10
ERCC1–118
CC 7 70 3 30 10 100 0 0 9 90 1 10
CT 43 67 21 33 56 88 8 12 55 86 9 14
TT 25 61 16 39 0.77 35 85 6 15 0.44 33 81 8 19 0.66
XRCC1–399
GG 9 60 6 40 13 87 2 13 15 100 0 0
AG 41 67 20 33 53 87 8 13 49 80 12 20
AA 25 64 14 36 0.86 35 90 4 10 0.90 33 85 6 15 0.17
Table 6 Incidence of diarrhoea according to MTHFR C677T genotype
Genotype Grades 0–2, n (%) Grades 3–4, n (%) P
MTHFR 677
CC 40 (38) 3 (27)
CT 51 (49) 3 (27)
TT 14 (13) 5 (45) 0.02
a
aFisher’s exact test (TT vs CT/CT genotype).
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sPFS and OS. These data, together with our findings on the value of
MTHFR as a predictor of toxicity but not efficacy, reinforce the
complexity of the impact of these genetic changes in predicting
tailored chemotherapy treatments.
This biological substudy was conducted on three successive
phase II trials with prospectively collected information on
response, toxicity and survival outcomes. The large number of
samples available for analysis added to the strength of the study.
Genetic polymorphisms were analysed in tumour tissue rather
than germline DNA. Although the majority of pharmacogenetic
studies have been performed in germline DNA, almost complete
concordance between germline and somatic DNA has been found
in terms of variants within pharmacogenetic genes (Marsh et al,
2005; McWhinney and Mcleod, 2009).
In conclusion, this study found significant associations between
the ERCC1-118 CC genotype and improved PFS and between the
MTHFR 677 TT genotype and grade 3 or 4 diarrhoea after FOLFOX
treatment. The present findings indicate that TP53 mutation, Kras
mutation and MSI are unlikely to be clinically useful molecular
markers for the prediction of response to FOLFOX chemotherapy
in mCRC. Similarly, the MTHFR C677T, ERCC1-118 and XRCC1-
399 polymorphisms were not associated with clinical response
to FOLFOX. Our observations on the association of ERCC1-118
and MTHFR C677T polymorphisms for response and toxicity,
respectively, to FOLFOX in mCRC require confirmation in large
prospective studies. Emerging information in this area based on
prospective trials should lead to clinically useful information
becoming available in the future.
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